Business Context and Reporting Period
Alterity Therapeutics Limited, a development stage enterprise based in Melbourne, Australia, filed this Form 6-K on January 8, 2024, covering the month of January 2024. The filing serves to incorporate a Notice Under Section 708A by reference into the company's active Registration Statements on Form S-8 and Form F-3.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, this specific Form 6-K focuses on regulatory notice rather than financial performance reporting.
Material Changes
No material changes in financial position or operations are detailed in this document. The primary content is the submission of Exhibit 99.1, a Notice Under Section 708A.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or specific risk factors. The document is a procedural filing to update registration statements with a regulatory notice.
Investor Verification Checklist
- Verify the contents of the Notice Under Section 708A (Exhibit 99.1) referenced in this filing.
- Review the company's most recent Form 20-F for actual financial statements and operational updates.
- Confirm the status of the referenced Registration Statements (S-8 and F-3) for potential capital raising activities.